ADVFN Logo ADVFN
시장 데이터
뉴스
도구
시장
팔로우

Hot Features

피드 팔로우

Follow Feed 커뮤니티에서 거래자 및 투자자와 연결하세요.

실시간 옵션 플로우

포괄적인 옵션 데이터를 탐색하고 옵션 흐름으로 고급 필터를 사용하세요.

모니터

터미널 모니터로 주식 및 자산 관심 목록을 구성하고 모니터링하세요.
로그인 Premium Icon프리미엄 Help Menu
S&P 500
5,264.14
-0.81%
US Tech 100
18,142.80
-0.47%
다우존스 지수
39,066.80
-1.52%
Bitcoin
67,063.10
-2.95%
Registration Strip Icon for discussion 같은 생각을 가진 투자자들과 토론할 수 있는 활발한 포럼에서 상호 작용하려면 등록하세요.
등록
  1. 홈
  2. 인베스팅
  3. 주식
  4. 미국
  5. NASDAQ
  6. ImmunityBio Inc (IBRX)

  7. ImmunityBio Inc (IBRX) 뉴스

IBRX

ImmunityBio (IBRX)

ImmunityBio Inc
일자:
정렬 기준:
 검색 관련기사 보기:NASDAQ:IBRX
일자시간출처헤드라인심볼기업
2024/05/1722:00Business WireConnecting the Dots of ANKTIVA’s Triangle Offense: A Deep Dive with Dr. Patrick Soon-Shiong and Dr. Ashish Kamat in a Three-Part UroToday PodcastNASDAQ:IBRXImmunityBio Inc
2024/05/1006:00Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
2024/05/0721:00Business WireImmunityBio Completes GMP Drug Substance Manufacturing Sufficient for 170,000 Doses of ANKTIVA®NASDAQ:IBRXImmunityBio Inc
2024/05/0305:04Business WireImmunityBio, Serum Institute of India Agree on an Exclusive Arrangement for Global Supply of Bacillus Calmette-Guerin (BCG) Across All Cancer TypesNASDAQ:IBRXImmunityBio Inc
2024/04/3021:00Business WireImmunityBio Executive Chairman Dr. Patrick Soon-Shiong to Discuss ANKTIVA® Approval in Fireside Chat at the Annual Conference of the American Urological AssociationNASDAQ:IBRXImmunityBio Inc
2024/04/2513:03Business WireImmunityBio Announces Positive Overall Survival Results of Anktiva Combined With Checkpoint Inhibitors in Non-Small Cell Lung Cancer; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung CancerNASDAQ:IBRXImmunityBio Inc
2024/04/2310:56Business WireImmunityBio Announces FDA Approval of ANKTIVA®, First-in-Class IL-15 Receptor Agonist for BCG-Unresponsive Non-Muscle Invasive Bladder CancerNASDAQ:IBRXImmunityBio Inc
2024/03/0623:00Business WireNIAID-Sponsored Study Shows N-803 Combined with Neutralizing Antibodies Could Lead to Sustained HIV Viral Control After Discontinuation of Antiretroviral TherapyNASDAQ:IBRXImmunityBio Inc
2024/03/0523:00Business WireN-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure StudyNASDAQ:IBRXImmunityBio Inc
2024/02/2706:43Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/02/2706:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/02/2706:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/02/2411:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
2024/02/2123:00Business WireImmunityBio Announces Full Accrual of First Two Phases of Cancer Vaccine Trial in Participants with Lynch Syndrome and Initiation of Randomized Controlled Phase of the TrialNASDAQ:IBRXImmunityBio Inc
2024/02/0711:14Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/02/0523:00Business WireImmunityBio Quality-of-Life Study in BCG-Unresponsive Bladder Cancer Trial Indicates Improved Physical Function in the 71% Complete Responders Suggesting a Favorable Risk-Benefit Ratio for N-803 Plus BCGNASDAQ:IBRXImmunityBio Inc
2024/02/0309:38Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/02/0309:33Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/01/0411:59Edgar (US Regulatory)Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]NASDAQ:IBRXImmunityBio Inc
2024/01/0411:41Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/01/0411:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IBRXImmunityBio Inc
2024/01/0220:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IBRXImmunityBio Inc
2024/01/0220:00Business WireImmunityBio Announces $320 Million Investment by Oberland Capital, with $210 Million Funded at Closing, Bringing Total Financing in 2023 to $850 MillionNASDAQ:IBRXImmunityBio Inc
2023/11/1623:00Business WireImmunityBio to Participate in 35th Annual Piper Sandler Healthcare ConferenceNASDAQ:IBRXImmunityBio Inc
2023/11/0911:28Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IBRXImmunityBio Inc
2023/11/0723:00Business WireFirst Data for ImmunityBio’s Memory Cytokine-Enriched NK Cells in Small Cell Lung Cancer at SITC Meeting Show Promising Anti-tumor ActivityNASDAQ:IBRXImmunityBio Inc
2023/10/2701:03Dow Jones NewsImmunityBio Shares Rally as FDA Accepts N-803 ResubmissionNASDAQ:IBRXImmunityBio Inc
2023/10/2622:00Business WireFDA Accepts ImmunityBio’s BLA Resubmission as Complete and Sets New PDUFA DateNASDAQ:IBRXImmunityBio Inc
2023/10/2400:00Dow Jones NewsImmunityBio Shares 11% Higher on License Application Resubmission for N-803NASDAQ:IBRXImmunityBio Inc
2023/10/2322:00Business WireImmunityBio Announces Biological License Application Resubmission for N-803 in BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer Carcinoma-In-SituNASDAQ:IBRXImmunityBio Inc
 검색 관련기사 보기:NASDAQ:IBRX

최근 히스토리

NASDAQ
GOOGL
Alphabet
NASDAQ
MSFT
Microsoft
AMEX
SPY
SPDR S&P 500
NASDAQ
AAPL
Apple
NYSE
MRK
Merck
SPI
SP500
S&P 500
USOTC
RHHBY
Roche (QX)
NYSE
NKE
Nike
NASDAQ
AMZN
Amazon.com
NASDAQ
NVDA
NVIDIA
USI
USTECH100
US Tech 100
USOTC
BASFY
BASF (QX)
CCOM
US30
US 30
NYSE
BAC
Bank of America
CCOM
US500
US 500
Delayed Upgrade Clock
ADVFN Logo

대한민국
회사 소개
사업
Popular
앱 받기

도움 및 지원받기: kr-support@advfn.com

ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관

© 2024 ADVFN PLC - 모든 권리 보유